Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BELR has been upgraded to Pink Current
https://www.otcmarkets.com/stock/BELR/security
Recent & Easily Verifiable Facts of KEGS:
KEGS was profitable in the 2nd, 3rd & 4th Quarter of 2024.
KEGS has verifiable assets, 4 properties in New York..
KEGS has 4 active liquor licenses in the State of New York.
KEGS is now delivering beer to 45 states plus DC.
KEGS beer is available to purchase in Canada.
KEGS 1812 beer has won multiple awards in multiple years in multiple competitions.
KEGS recently won New York Amber Ale Brewer of the Year Award.
KEGS has purchased a new restaurant in Watertown, NY now named 1812 On The River.
KEGS has a restaurant in Sackets Harbor, NY now called 1812 on the Lake.
KEGS has its own brewery & bottling processing facility in Watertown that is 13,000 sq feet (different than the restaurant).
KEGS has addressed the $13.7 million in debt and the note holders have tentatively agreed not to convert until market cap reaches $100 million
KEGS has not issued any new shares since March 1st, 2024... NO DILUTION in over 1 year!!! (about 2k shares added presumably for rounding up after reverse split)
BELR is just another SCAM...... ZERO revenue. ZERO cash on hand and in debt for MILLIONS.
Around 67 million shares of dilution has taken BELR from ~ $4.00 to ~ $ .0025. What is going to happen when there is more dilution? lololol
.
$BELR grace period removed. tiny float https://www.otcmarkets.com/stock/BELR/security
BIEL ACTIPATCH HUGE HIT IN TAIWAN!
https://www.actipatchtw.com/general-1
https://finance.yahoo.com/news/bioxytran-completes-dose-optimization-antiviral-130000915.html
Got any questions about huge a deal this is folks, ask me.
This is the worlds first 60+ virus broad spectrum antiviral and long haul chronic disease like Long Haul Covid, EB virus Triggered MS, Bird flu virus, CFS (Chronic Fatigue Syndrome, triggered by trace virus infections that never go away like Herpes....) cure
This is the worlds first 60+ virus broad spectrum antiviral and long haul chronic disease like Long Haul Covid, EB virus Triggered MS, Bird flu virus, CFS (Chronic Fatigue Syndrome, triggered by trace virus infections that never go away like Herpes....)
It is also the key to a 300% increase in the $MRK Merck Cancer drug #Keytruda that could be the next news of JV funded trial.
Any little bit!!! This company is REAL!!
Nice......Funding helps......
Z
$DTERF Colosseum Rare Earths Drilling Program
Dateline is advancing plans for a rare earth drilling program at Colosseum, located just 6 miles north of the Mountain Pass Rare Earth Mine. This initiative supports U.S. federal goals to secure domestic supplies of critical minerals vital for technology, defense, and clean energy. The program builds on Colosseum's established gold resource, which includes a JORC-2012 compliant Mineral Resource Estimate of 27.1 million tons at 1.26 g/t gold for 1.1 million ounces (41% Measured, 26% Indicated, 33% Inferred
The future gold miner with several properties in North America: Watch how Brixton Metals Provides Exploration Plans for Gold and Copper Drill Targets for its Fully Funded 2025 Program at its Thorn Project:
https://www.barchart.com/story/news/32234526/brixton-metals-provides-exploration-plans-for-gold-and-copper-drill-targets-for-its-fully-funded-2025-program-at-its-thorn-project
$LITM Snow Lake Energy Surges Forward with Major Uranium Developments Across Three Continents
https://allcapresearch.com/f/snow-lake-energy-litm-expands-global-uranium-push
BIEL +200% GOLDEN CROSS, BLUE SKY BREAKOUT!
$MAJI mega news can drop any minute folks. Nano Float, Nano OS, and it's a new company with huge trial data due on Brain Cancer trials. Also fits into #Trump's Push to move drug manufacturing back to the USA, and the new MAJI company has already gone into production of the new Star Trek Borg Nano Probe production of Plant based Nano drug delivery particles known as Exozomes (Google it). Would not be Surprised to see $MRK take a serious Interest in $MAJI
A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells
ORLANDO, FL / ACCESS Newswire / April 21, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc. , a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to share published information about the therapy being used in our current Glioblastoma ("GBM") study.
Dr. Marvin Hausman , our Chief Science Officer, revealed Thursday live on a Spaces interview that a paper had been published showing that the NANOG Expression therapy reduced the resistance of the Cancer stem cells in Glioblastoma. In fact, the paper goes on to reveal that when temozolomide ("TMS") was used on its own at its highest concentration, less than 20% of the GBM cells were killed. When the GBM cells were treated with shRNA targeting NANOG or OCT4 in combination with TMZ, the level of cell death was significantly higher compared to that of the TMZ treatment alone, suggesting that the inhibition of NANOG or OCT4 increased the efficacy of TMZ.
The full paper may be read here: https://pmc.ncbi.nlm.nih.gov/articles/PMC10297980/
Matt Dwyer , our President, stated, "I was listening to the Spaces interview and couldn't believe what I was hearing. I had no clue this information existed. I know the current study and its findings, but this was mind-blowing. I suggest everyone go listen to Dr. Hausman and pay attention to the excitement in his voice as he discusses the ongoing study."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology.The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
$NGCG This is thin for a Trip-000...Can move fast out of trips!
🎯 Swinging here for 300-400%
lol..........
Z
$CBLO is positioning for a breakout. New expansion into 14MW Bitcoin mining, Ethereum validator stacking on deck, and a strategic Cardano footprint—C2 Blockchain is bridging legacy OTC roots with real crypto infrastructure. Don’t sleep. #CBLO #BTC #ETH #ADA #CryptoMining #ShortSqueeze
Weekend Warrior funnies:
I just ordered $IFUS Intact Digest.........
Z
The more I look at $IFUS, the more shocking the potential is that I see:
In 6 decades I have never seen a bigger opportunity that can solve the source of inflation, reduce food costs, restore our health, reduce the number of Cancer cases in a huge way, limit Climate Change risks, and damage and reduce the risk of a stupidity driven by ignorance Extension level event, with game changer technology, and save the planet.
Why $IFUS Intact digest works, and does so many things to improve animal and Human health:
https://impactfusionbrands.com/product/intact-digest/
Most people are magnesium deficient. Some so deficient they drop dead during heavy sports events.
AI Overview
Learn more
The global digestive health supplements market was valued at $51.62 billion in 2023 and is projected to grow to $105.48 billion by 2033, with a CAGR of 8%. This growth is driven by increasing awareness of gut health and its impact on overall well-being.
The U.S. digestive health products market alone is expected to reach $18.66 billion by 2033, according to GlobeNewswire
$IFUS Intact Digest is a way bigger deal, way bigger market than I thought. And we all know now that no one in the world has anything close to what is Intact Digest is and does
Fry them all!!!...........
Z
$IFUS is a super strong buy the dip today
Shorts on $IFUS showed us their desperate losers hand late yesterday, and they just dug a deeper hole to China. Here is the evidence.
1) The Cost to borrow is rising again. OUCH
2) Shorts borrowed the difference between, 4.8 Mil - 1.2 mil = 3.6 Million IFUS shares borrowed by the criminals Dowe-Cheatem-Andhow street
3) Retail did not sell, retail bought, and has been buying, and bear trapping the fools-are-us Shorts. MM/Hedge fund Shorts covered shorts with shorts for a day, with obvious easy to spot wash trades. They have even been panic borrowing, and returning hour by hour as you can see here:
When news drops, and there is plenty of death-star news due already, the shorts that are borrowing to cover, daily, will paying way higher prices borrow or just buy back.
They never seem to learn, making me think they are operated by math challenged kindergarden Uber-drop outs and clowns.
$MAJI is moving fast into the Exozone Oncology field. Glioplastoma Brain Cancer. , trial for boosting the $MERC Cancer drug performance.
**Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series.**
ORLANDO, FL / ACCESS Newswire / April 30, 2025 / MARIJUANA INC. (OTCPINK:**$MAJI**), dba Exousia Pro, Inc., **a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, is launching a weekly web series titled "Ask Dr. Hausman."**
Our chief science officer, Dr. Marvin Hausman, will join Exousia Pro as a consultant; his contract is being finalized now. **Dr. Hausman was instrumental in creating Exousia AI **and **establishing the Glioblastoma study with UCF, and will assist Exousia Pro in advancing therapies using our plant-based exosomes. Exousia Pro will launch a new web series, "Ask Dr. Hausman." Shareholders will be able to email questions that Dr. Hausman will answer weekly. Dr. Hausman will also share updates on various studies conducted, our FDA submissions, and future IND trials.**
Matt Dwyer, our President, stated, "Exousia Pro is very fortunate to have Dr. Hausman working with us. **His rolodex of scientific and financial professionals in the biotech world is priceless. We believe that Dr. Hausman can open doors for Exousia Pro that we could never do.** I met Marvin about 1 year ago and have established a strong relationship with him, and I look forward to working closely with him in advancing Exousia Pro."
About Us
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
https://www.exousiapro.com
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/exousia-pro-will-launch-a-web-series-with-our-new-consultant-1021683
LMAO.......yeah.....really.....if aliens visited the earth they'd probably think dogs and cats were the rulers.......
Z
Very nice!!
Z
Huge news out on $MAJI today
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/exousia-pro-finishes-preclinical-trial-for-glioblastoma-ahead-of-sche-1021225
https://www.otcmarkets.com/stock/MAJI/news/Exousia-Pro-Finishes-Preclinical-Trial-for-Glioblastoma-Ahead-of-Schedule---Bolstering-Orphan-Drug-Application?id=475208
Nano Float and OS, and could end up with a deal with $MERC $$$$$$$$$$$
Under the radar news. Brain cancer #Glioblastoma
$RDAR: Raadr Inc., Doing Business as Telvantis, Selected for an Interview on the Floor of the NYSE
NEW YORK - April 23, 2025 (NEWMEDIAWIRE) - Raadr Inc., doing business as Telvantis (OTC: RDAR) ("Telvantis" or the "Company"), a U.S.-based technology-driven telecommunications and enterprise solutions provider, is pleased to announce the receipt of an interview request to be filmed on the floor of the NYSE.
The NYSE floor interview date is set for April 23, 2025. The release of the interview to the public will be on April 30, 2025.
The selection of topics will include the following:
Acquisitions and corporate expansion plans
PCAOB audit updates
Revenues
"Both shareholders and the Company have gone through some amazing transformations over the past few months as we completed Phase 1 and moved on to Phase 2 of our 2025 growth strategy. To be selected for an interview on the floor of the NYSE is an honor and testament to what we are building here at Telvantis," commented Daniel Gilcher, CFO of Telvantis, who will be representing the Company on the floor of the NYSE.
About Telvantis
Raadr Inc., now doing business as Telvantis (OTC: RDAR), is a U.S.-based telecommunications company delivering advanced solutions to operators, enterprises, and network providers worldwide. Through its recent acquisitions of operations in the U.S. and Ireland, Telvantis has strategically expanded its portfolio to encompass cutting-edge 5G technologies, cloud-based communications platforms, and enterprise-grade services. This expansion, combined with a forward-thinking approach, positions Telvantis for accelerated growth and market leadership in the evolving telecommunications landscape.
Forward-looking statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the Company's current expectations regarding future events and are based on management's beliefs and assumptions. Actual results could differ materially from those projected due to various factors, including market conditions, competition, and the successful integration of acquired operations. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
Investor Relations Contact
Raadr Inc. (doing business as Telvantis)
1680 Michigan Avenue, Suite 700
Miami Beach, FL 33139
Email: ir@telvantis.com
Website: www.telvantis.com Twitter/X: @Telvantis
LinkedIn: Telvantis
News Source: Telvantis Inc.
Best Scanner for Stocks:
https://DDAmanda.com
Z
Good morning sir. If you all recall some of the stocks I pounded the table on here for years, have made it the stadium Lights.
$OPXS I pounded the table on back in 2014. It hit about $8.80 on Nasdaq about 18 months ago. They Bough back shares, before the Nasdaq Uplist the last 3 years. All the way from sub penny in 2014
$IFUS is on the same path, and going Global. The market and products they have yield a $200/share upside future. Already made a Massive deal to expand to India.
$GEVI went from .04 (where I bought) to about a high of $1.50
$BDCO ran from penny land when I called the buy to about $8.xx/share in 18 months
$BIXT filed an S-1 after the SEC Screwed up (Millions died of Covid19 because of the SEC screw up), and BIXT is on verge of JV deals with Firms like $MERC and about to solve the global Birdflu problem. They also got 10 Million in funding for their synthetic blood oxygen carrier Molecule that can pass through blood clots, to get O2 to the heart muscle and Brain. etc, stopping stroke or blood clot lack of O2 organ and tissue damage.
Bird Flu? Also known as #H5N1:
https://www.cidrap.umn.edu/avian-influenza-bird-flu/mexicos-fatal-h5n1-case-involved-d11-genotype-which-has-been-tied-serious
Lastly the $BIXT Prolectin-M is expected to be able to triple the cancer cure rate of $MERCs #Keytruda cancer cure drug, which is a Billion dollar a year business, but only about 25% effective because of Galectin-3 loads in cancer patients that keep Keytruda from working.
$BIXT Prolectin-M can block Galectin-3s, and has passed the Human safety trials with only perfect drug trial in over 10 years.
BIXT will take the JV (Partnership) trials and Licensing route with Folks Like MERC, for each separate application and product. No sell out plans on this one.
BIXT has hundreds of applications for its Galectin-Antagonist Bio-technology All Virus antiviral platform. USDA funding, 100 Million dollars, is going to be tapped with a grant application once the Univ of Georgia data on stopping Birdflu with Prolectin-M is complete. This is only weeks away.
That's all it would take........a partnership/buyout from a big drug company.......
Z
Pretty impressive...........
Z
Most folks will miss the huge ride coming on $IFUS.
They are hiding in plane site, and already going global. Products restore health, and save customers up to 85% of the cost or feed cattle, chickens, goats, and the game changer Mulch could turn deserts in fields of crops. They have Gov funded Universities, 4-5 at last count, on board doing IFUS Product testing,
2 possible explosive news events on tap for $BIXT, Billion dollar deal JV with Cancer cure maker of Keytruda, $MERC and or a $100 Million dollar grant money tap for BIXT for the only known product that can stop birdflu in Chickens and Humans and cattle. Non toxic, 60+ virus Antiviral, and its patented.
The latest long term upside projections for $IFUS look as nuts as Amazon, Google and Tesla upsides looked in the early days of those stocks.
Marc added Chicken feed using SGP+ and expansion to another over seas country, not just India to the list days ago. They came to IFUS!!!!!
If the 400% Q to Q revenue growth holds or increases in the financials coming in 2 weeks, shorts will never know what hit them. Time is running out to load. Some revenue and profit projections based on the 85% gross Profit margin, and expected share buy backs and dividends have now passed $200/share upside for this sleeper.
$MAJI Update, one of many:
A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells
ORLANDO, FL / ACCESS Newswire / April 21, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc. , a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is pleased to share published information about the therapy being used in our current Glioblastoma ("GBM") study.
Dr. Marvin Hausman , our Chief Science Officer, revealed Thursday live on a Spaces interview that a paper had been published showing that the NANOG Expression therapy reduced the resistance of the Cancer stem cells in Glioblastoma. In fact, the paper goes on to reveal that when temozolomide ("TMS") was used on its own at its highest concentration, less than 20% of the GBM cells were killed. When the GBM cells were treated with shRNA targeting NANOG or OCT4 in combination with TMZ, the level of cell death was significantly higher compared to that of the TMZ treatment alone, suggesting that the inhibition of NANOG or OCT4 increased the efficacy of TMZ.
The full paper may be read here: https://pmc.ncbi.nlm.nih.gov/articles/PMC10297980/
Matt Dwyer , our President, stated, "I was listening to the Spaces interview and couldn't believe what I was hearing. I had no clue this information existed. I know the current study and its findings, but this was mind-blowing. I suggest everyone go listen to Dr. Hausman and pay attention to the excitement in his voice as he discusses the ongoing study."
BIEL VA HUGE!
https://veteranrecovery.org/
Flagship product RecoveryRX now available to all veterans at all VA's!
Ted Fienning
BioElectronics Corporation
Harvard University
Marine Corp Pilot
"Share with any veteran you know using the VA: RecoveryRX is an FDA-approved pain management device now available nationwide at every VA. Non-opioid, non-invasive, and available by asking your VA provider."
An American hero gives a fantastic testimonial about Bioelectronics flagship product - RecoveryRX!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980584
DMN (nasdaq ticker) @OTC 0.003/4 pps. $3.5m MC, $100m potential revs inside $106.8 Billion World MotorCycle Industry..
DD Recent Technical Stats: https://ih.advfn.com/stock-market/NASDAQ/damon-DMN/historical
Followers
|
676
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50381
|
Created
|
08/26/13
|
Type
|
Free
|
Moderator TenTimesPay | |||
Assistants Papa Bear BLULLISH yankee2 $Pistol Pete$ |
Posts Today
|
0
|
Posts (Total)
|
50381
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |